Cold Acclimation as a Modulator of Brown Adipose Tissue Function in Adults With Obesity

NCT05468151 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2026-05-11

No results posted yet for this study

Summary

This study will investigate the effects of at least 12 weeks of weekly cold water immersions (water temperature 18ºC) on BAT perfusion in individuals with obesity. BAT oxygen uptake and tissue perfusion will be measured using 15O-O2 and 15O-H2O PET-CT, at room temperature and after cold exposure. In addition, BAT glucose uptake will be measured using 18F-FDG after 2 hours of cold exposure and BAT NEFA uptake will be analyzed using 18F-FTHA at room temperature.

To understrand the metabolic effects of BAT activation in individuals with obesity and how the cold water immersions affect the BAT perfusion in humans is critical for the development of new strategies to treat obesity and its comorbidities.

Conditions

Interventions

OTHER

Cold acclimation

The cold water immersions will last 30-60 minutes per day and the volunteers will undergo 2-3 cold immersions per week.

OTHER

Intervention Control group - volunteers with obesity

Participants with obesity in the control group will undergo PET/CT scans at baseline and 12 weeks after the first scan.

OTHER

Acute cold exposure

All participants (lean and with obesity) will undergo PET/scans after 2 hours of cold exposure to investigate BAT perfusion and BAT glucose uptake.

Sponsors & Collaborators

  • University of Turku

    collaborator OTHER
  • University of Barcelona

    collaborator OTHER
  • University of Ottawa

    collaborator OTHER
  • Turku University Hospital

    lead OTHER_GOV

Principal Investigators

  • Kirsi A Virtanen · Turku University Hospital

  • Francisco Acosta, PhD · Turku PET Centre

  • Mueez U-Din, PhD · Turku PET Centre

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-07-25
Primary Completion
2024-12-20
Completion
2026-12-01

Countries

  • Finland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05468151 on ClinicalTrials.gov